ESMO 2024 | Addressing key challenges in adjuvant therapy for renal carcinoma
Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines critical questions in the management of renal carcinoma, particularly regarding adjuvant therapy. He emphasizes the lack of effective biomarkers to identify patients who would benefit most from such treatments, and there is uncertainty about the best course of action for patients progressing on adjuvant therapy. Such strategies are needed to improve the cure rate and quality of life for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
